过敏性紫癜患儿应用孟鲁司特钠联合氯雷他定的机制及效果探讨  

Exploring the mechanism and effect of montelukast sodium combined with loratadine in children with allergic purpura

作　　者：丁粉芹 Ding Fenqin(Yancheng First Hospital Affiliated of Nanjing University Medicine College,Yancheng First People's Hospital,Yancheng,Jiangsu 224000,China)

机构地区：[1]南京大学医学院附属盐城第一医院,盐城市第一人民医院,江苏盐城224000

出　　处：《首都食品与医药》2024年第20期66-68,共3页Capital Food Medicine

摘　　要：目的探究孟鲁司特钠联合氯雷他定治疗过敏性紫癜患儿的作用.方法选取我院自2020年1月-2023年12月收治的116例过敏性紫癜患儿纳入研究.根据治疗方式不同,均分为联用组、单用组,每组各58例.单用组行孟鲁司特钠治疗,联用组在此基础上加用氯雷他定治疗.比较两组的治疗效果、炎性因子水平、症状改善时间及不良反应发生情况.结果联用组的治疗效果高于单用组(P<0.05);干预后联用组炎性因子水平低于单用组(P<0.05);联用组症状改善时间短于单用组(P<0.05);两组不良反应发生情况比较,无明显差异(P>0.05).结论孟鲁司特钠联合氯雷他定治疗能够改善过敏性紫癜患儿的治疗效果,降低炎性因子水平,缩短症状改善时间,且安全性较好,不良反应发生情况较少,具有临床应用价值,建议进一步推广.Objective To explore the effect of montelukast sodium combined with loratadine in children with allergic purpura.Methods A retrospective analysis of 116 children with allergic purpura admitted to our hospital from January 2020 to December 2023 were included in the study.According to the different treatment methods,they were divided into combined group and single group,58 cases each.Montelukast sodium alone,plus loratadine.The treatment effect,inflammatory factor level,time to symptom improvement and the occurrence of adverse effects were compared between the two groups.Results The treatment effect of the combined group was higher than the single group(P<0.05);the inflammatory factor level was lower than the single group(P<0.05);the symptom improvement time was shorter than the single group(P<0.05);the occurrence of adverse reactions between the two groups have no significant difference(P>0.05).Conclusion The combination therapy of montelukast sodium and loratadine can improve the treatment effect of children with allergic purpura,reduce the level of inflammatory factors,shorten the time for symptom improvement,and has good safety with fewer adverse reactions.It has clinical reference value and is recommended for further application.

关 键 词：过敏性紫癜 孟鲁司特钠 氯雷他定 治疗效果 炎性因子水平 

分 类 号：R554.6[医药卫生—血液循环系统疾病]